Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493531 · ClinicalTrials.gov registry record · Phase 3
Combining Lesinurad With Allopurinol in Inadequate Responders
A Phase 3 study of Gout, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 610
- Enrollment target
- 20
- Study locations
NCT01493531 is a Phase 3 study of Gout that has completed, run by Ardea Biosciences. The registered enrollment target is 610 participants, below the 8,870-participant average among 34 other Gout trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT01493531, a Phase 3 study of Gout, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 610 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Lesinurad
Study Locations (20)
California
- - Anaheim
- - Gold River
- - Irvine
- - La Jolla
- - Roseville
- - San Diego
- - San Diego
- - San Ramon
Arizona
- - Chandler
- - Mesa
- - Pheonix
Arkansas
- - Jonesboro
- - Jonesboro
- - Little Rock
Colorado
- - Colorado Springs
- - Denver
- - Glenwood Springs
Alabama
- - Mobile
Connecticut
- - Trumbull
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493531
The ClinicalTrials.gov registry entry for NCT01493531 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 610 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,870-participant average among 34 other Gout trials with a reported enrollment target (93% lower). The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01493531 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01493531 about?
NCT01493531 is a clinical study titled "Combining Lesinurad With Allopurinol in Inadequate Responders". This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.
What is the current status of trial NCT01493531?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 610 participants. The study started on 2011-12. Estimated completion is 2014-07.
What conditions does trial NCT01493531 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT01493531?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Lesinurad (DRUG).
Who is sponsoring clinical trial NCT01493531?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01493531 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
COMPLETED · Phase 3
-
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
COMPLETED · Phase 3
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.